Navigation Links
Abbott Announces Positive Data From ABSORB Trial on Its Bioresorbable Vascular Scaffold Technology
Date:3/15/2010

restore blood flow by opening a clogged vessel and providing support until it is healed. Once the vessel can remain open without the extra support, the bioresorbable scaffold is designed to be slowly metabolized by the body, and is completely dissolved over time. Since a permanent implant is not left behind, a vessel treated with BVS has the ability to ultimately move, flex and pulsate similar to an untreated vessel. The potential to restore these naturally occurring vessel functions, or vascular restoration therapy, is what makes Abbott's BVS unique in the field of cardiology.  

About the ABSORB Clinical Trial

The ABSORB trial is a prospective, non-randomized (open label), two-phase study that enrolled 131 patients from Australia, Belgium, Denmark, France, the Netherlands, New Zealand, Poland and Switzerland. Key endpoints of the study include assessments of safety – MACE and treated site thrombosis rates – at 30 days; six, nine, 12, 18 and 24 months; with additional annual clinical follow-up for up to five years, as well as an assessment of the acute performance of the bioresorbable vascular scaffold, including successful deployment of the system. Other key endpoints of the study include imaging assessments by angiography, intravascular ultrasound (IVUS), optical c
'/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
2. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
3. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
4. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
5. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
6. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
7. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
8. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
9. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
10. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
11. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Influenza will affect as many as 200,000 people ... United States as high as 49,000 people.  The ... from person to person in respiratory droplets of coughs and ... death, but kills much fewer people each year than the ... fluids including sweat, saliva, blood and other bodily fluids. The ...
(Date:10/22/2014)... , Oct. 22, 2014 InVivo Therapeutics Holdings ... is revolutionizing spinal cord injury (SCI) treatment ... shown to outperform in tissue regrowth in the spinal ... Made from an FDA approved polymer, the scaffold ultimately ... harmless to the human body. NVIV has recently attracted ...
(Date:10/22/2014)... , Oct. 22, 2014 WHEN: Wednesday, October ... complimentary registration available at: http://bit.ly/1yStiU9 ... Vidyasekar and Visionary Innovation Research Group Senior ... electricity, self-assembling materials, nanobots and flexible electronics ... will transform our lives in the coming ...
Breaking Medicine Technology:WholeHealth Products is proud to be releasing its Influenza A and B combo test, on the heels of the announcing of its phase 2 completion of the Rapid Ebola Test 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4
(Date:10/22/2014)... Akeso Biomedical, Inc. , a privately ... bacterial infections, microbial biofilms, and chronic wounds, announced that ... directors. , Dr. Sinskey is a ... Institute of Technology, or MIT. He has been a ... also holds positions as Co-Director of the Malaysia-MIT Biotechnology ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. ... fertilization (IVF) are only about half as likely as white ... new research indicates, and the racial disparity persists even when ... percent of white patients became pregnant after IVF, compared to ... 4,000 IVF cycles over two years to tease out the ...
(Date:10/22/2014)... Tara Haelle HealthDay Reporter , ... young adult men may lead to increased blood pressure, according ... a similar rise in blood pressure for young adult women ... young adult women drank lightly or moderately, their risk of ... "This finding parallels studies in older adult men and ...
(Date:10/22/2014)... TUESDAY, Oct. 21, 2014 (HealthDay News) -- Measures taken ... plantation in Ebola-ravaged Liberia may have limited the spread ... researchers report. The Firestone Natural Rubber Co. provides ... and residents of nearby densely populated communities. Between ... and suspected Ebola cases among those 80,000 people. That ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, 2014 (HealthDay News) -- ... NBC News in Liberia has cleared the virus from ... Medical Center in Omaha, where he had been treated for the ... confirmed by the U.S. Centers for Disease Control and Prevention found ... NBC News reported Tuesday night. "Recovering from Ebola is ...
Breaking Medicine News(10 mins):Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3
... of Miami (UM) Department of Psychology participated in a multi-site ... Spectrum Disorder (ASD). The study is one of the first ... with autism. The findings are published online in the ... Disorders . The report concludes the first phase ...
... By Serena Gordon HealthDay Reporter , THURSDAY, May ... year is especially tough, say allergy experts. "Everyone ... the worst year ever for allergies," said Dr. David Rosenstreich, ... Center in New York City. But this year those ...
... French . , Montreal, May 19, 2010 Caring ... a taxing experience marked by personal sacrifices and psychological problems. ... the University of British Columbia has found family caregivers can ... symptoms unless they refocus their priorities and lighten their ...
... A University of Missouri researcher has found that eating ... satiety and reduces hunger throughout the day. In addition, ... that eating a protein-rich breakfast reduces the brain signals ... knows that eating breakfast is important, but many people ...
... Crohn,s patients in a research study at Penn ... a chronic inflammatory condition of the gastrointestinal tract ... loss. Treatments for Crohn,s disease are designed to ... rare but serious side effects, including infections and ...
... Dozens of studies on whether moderate exercise can ... up to an apparent contradiction: it seems to work ... out in treatment trials. A new study may explain ... The explanation suggested in the results of research led ...
Cached Medicine News:Health News:Validating preschool programs for children with autism 2Health News:Springtime and the Sneezin' Is Easy 2Health News:Springtime and the Sneezin' Is Easy 3Health News:Bearing through it: How caregivers of mentally ill kin can cope 2Health News:Eat a protein-rich breakfast to reduce food cravings, prevent overeating later, researcher finds 2Health News:Use of naltrexone reduces inflammation in Crohn's patients 2Health News:Exercise helps women fight smoking cravings, but effect is short-lived 2
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
... Occipital Mandibular Immobilizer) A completely adjustable ... or hypertension positioning and immobilization. Offers ... Philadelphia™ collar and a halo-type brace.,Mandibular ... Removable chin plate allows for patient ...
Ezy Wrap® Economy Contour Cervical Collar Medium-density urethane foam. Synthetic white stockinette cover. Reverses for flexion or extension. (Contact closure. Hand wash. Air dry. 10/pack.)...
... Exo-Static™ Collar for cervical ... positions. Automatic adjustment allows widening ... lowered under chin. Velcro® fasterner.,Exo-Static™ ... backward movement, even in neutral ...
Medicine Products: